ECTRIMS

🎥 🍿 Direct from the auditorium of this year's Opening Session, ECTRIMS is proud to share our 40th anniversary film: "What is ECTRIMS?" This short film traces the rich history of ECTRIMS. It starts with the vision of one of our pioneering founders, Professor Otto R. Hommes. And it ends with a tribute to our collective achievements, the incredible progress we’ve made since our humble beginnings, and the community we’ve built over the last four decades. Thank you for being part of this incredible journey #ECTRIMS2024 PLAY HERE 👉 https://bit.ly/3MWzrJQ ___________ Featuring: Bernard Uitdehaag Amsterdam UMC | Frederik Barkhof VU University Medical Center - Amsterdam Neuroscience | Maria Pia Amato Università degli Studi di Firenze | Xavier Montalban CEMCAT (Centre d'Esclerosi Múltiple de Catalunya) | Alan J Thompson UCL | Ludwig Kappos University Hospital Basel | maria trojano Università degli Studi di Bari | Mar Tintore Subirana CEMCAT (Centre d'Esclerosi Múltiple de Catalunya) | Powered by Congrex Switzerland

🚀 Something exciting is on the horizon at ECTRIMS! Over the last year we’ve been working behind the scenes to build a personalised and seamless ECTRIMS experience designed just for you. Soon, you’ll be able to: • Connect with 35,000 MS professionals globally🌍 • Stay updated on the latest research 🧠 • Explore fellowships and educational programmes 🎓 • Access everything ECTRIMS in one centralised platform 📚 Stay tuned—myECTRIMS is coming soon!

⏰ How early is early enough? This month, the Multiple Sclerosis Journal (MSJ) features the first study to examine healthcare use in the three years preceding the diagnosis of radiologically isolated syndrome (RIS). This investigation was conducted by linking two databases: the French MS Registry (OFSEP) and the French National Health Insurance Data Registry (SNDS), which covers 98% of the national population. People with RIS had increased neurologist visits before diagnosis, primarily due to common comorbidities such as migraines. Despite the greater use of healthcare in this cohort, the study did not find there was evidence of a systemic prodrome in these individuals with RIS. Read more here ➡️ https://bit.ly/4hUOXDD #MS #MSResearch #MRI #imaging Sage

🌟 Excited for #ECTRIMS2025 in Barcelona? Now is the perfect time to start planning your trip to the premier multiple sclerosis congress. While we await the opening of Congress registration, we're here to ensure your accommodation booking is seamless and stress-free. Browse and book your ideal hotel through our website before the best deals are gone! Book your ideal stay today ➡️ https://bit.ly/40Hl2t0

One in 10 cases of multiple sclerosis (MS) begins in childhood. In our latest MS Research Spotlight, we focus on paediatric MS.👦👧 🧠 While children with MS recover quickly from attacks, they experience high disease activity with frequent relapses and brain lesion accumulation. Professor Yael Hacohen from University College London UCL says: “Children recover from attacks very quickly and with very little disability. This, along with the fact that MS is very rare in children, can sometimes lead to a delay in diagnosis. However, once they undergo a magnetic resonance, it becomes clear that they have MS.” “The ongoing smoldering damage in children with MS is also evident from the consistent divergence from the expected growth of the brain, and especially of the thalamus. In contrast, children with MOGAD do not show such a linear divergence," adds Professor Giulia Fadda of the University of Ottawa in Canada. 💉 Early treatment of children with MS with highly effective therapies is associated with a substantial reduction in the risk of first relapse. However, long-term studies on the safety of high-efficacy treatments are still needed. Discover more insights about paediatric MS in our latest MS Research Spotlight: https://bit.ly/42OajhR #MS #MOGAD #ChildrenwithMS #Earlytreatment #paediatricMS

ICYMI: Decoding Fatigue in MS 😴 Fatigue is a common symptom of multiple sclerosis (MS), but there is still a lot to be learned about it. "Fatigue tends to be overlooked in the clinical setting, probably because assessing fatigue is both time consuming and frustrating. We tend to think of fatigue as a hard-to-treat symptom," says Anne-Laure Dubessy of Hôpital Pitié Salpétrière AP-HP, Assistance Publique - Hôpitaux de Paris and co-chair of the ECTRIMS Scientific Communications Committee. 🔊 In our latest podcast episode, Dr. Dubessy and Iris-Katharina Prof. Dr. Penner of University Hospital Bern joined host Brett Drummond of MStranslate to discuss the challenges of managing fatigue and the latest research insights. 🎧 Listen here ⬇️ Web: https://bit.ly/42f9Pkm Spotify: https://spoti.fi/3PDZ8QI Apple: https://apple.co/4hgDqyj Don't miss our future episodes! Subscribe to The ECTRIMS Podcast on Spotify or Apple Podcasts. #MS #MSResearch #Neurology #Fatigue

ICYMI: See what's in our latest MS Research Update: ➡️ 🧠 Researchers from Institut du Cerveau – Paris Brain Institute reveal that monocytes from individuals with MS behave differently compared to those from healthy people. They have a reduced capacity to phagocytose myelin debris and process it after ingestion. This behaviour continues even when the macrophages are exposed to pro-regenerative signals. ➡️ 🤰Researchers found that in utero exposure to ocrelizumab does not appear to increase the risk of complications for the pregnancy or the infant. ➡️ “Will I have to take my treatment for the rest of my life?” is a common concern among people with MS starting their treatment. In some cases, “prudent de-escalation” of treatment may be considered, particularly for individuals aged 55 years or older who have shown no evidence of disease activity for at least 5 years. These are the conclusions from an ECTRIMS international workshop on this topic. Read more about these findings and more in our latest MS Research Update: https://bit.ly/4g5U3vi #MS #MSResearch #MSTherapeutics #Women’s Health #Ageing #pregnancy

💡 Did you miss the #ECTRIMS2024 on-demand sessions? While our on-demand platform is no longer available (don’t worry, the sessions are being moved to our online library and will be available soon), you can still catch up on the highlights of the breakthroughs in #MS research, diagnostics, and treatment strategies presented at ECTRIMS2024. 💻 Download the Best of ECTRIMS2024 Slide Decks across four content tracks: clinical, imaging and non-imaging biomarkers, pathogenesis, and therapy. Access the slide decks here: 🔗 https://bit.ly/3TqUzM2 #MSResearch #Neurology

🧳Let us help you score amazing hotel deals for #ECTRIMS2025 in Barcelona! While we wait for congress registration to open in a few weeks, why not lock in your hotel booking early? 🛏️ We’re here to make your accommodation planning easy and convenient. 💻 Book now through our website to access exclusive deals! ➡️ https://bit.ly/40Hl2t0

✨What’s new this month in MS Research? ➡️ 🧠 Researchers from @Institut du Cerveau – Paris Brain Institute reveal that monocytes from individuals with MS behave differently compared to those from healthy people. They have a reduced capacity to phagocytose myelin debris and process it after ingestion. This behaviour continues even when the macrophages are exposed to pro-regenerative signals. ➡️ 🤰Researchers found that in utero exposure to ocrelizumab does not appear to increase the risk of complications for the pregnancy or the infant. ➡️ “Will I have to take my treatment for the rest of my life?” is a common concern among people with MS starting their treatment. In some cases, “prudent de-escalation” of treatment may be considered, particularly for individuals aged 55 years or older who have shown no evidence of disease activity for at least 5 years. These are the conclusions from an ECTRIMS international workshop on this topic. Read more about these findings and more in our latest MS Research Bulletin: https://bit.ly/4g5U3vi #MS #MSResearch #MSTherapeutics #Women’s Health #Ageing #pregnancy